Mark J. Gemkow

479 total citations
15 papers, 389 citations indexed

About

Mark J. Gemkow is a scholar working on Molecular Biology, Pharmacology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Mark J. Gemkow has authored 15 papers receiving a total of 389 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Pharmacology and 7 papers in Cellular and Molecular Neuroscience. Recurrent topics in Mark J. Gemkow's work include Cannabis and Cannabinoid Research (7 papers), Pharmacological Receptor Mechanisms and Effects (5 papers) and Neurotransmitter Receptor Influence on Behavior (4 papers). Mark J. Gemkow is often cited by papers focused on Cannabis and Cannabinoid Research (7 papers), Pharmacological Receptor Mechanisms and Effects (5 papers) and Neurotransmitter Receptor Influence on Behavior (4 papers). Mark J. Gemkow collaborates with scholars based in Germany, United States and United Kingdom. Mark J. Gemkow's co-authors include Adam J. Davenport, Bart Ellenbroek, David J. Hallett, Andrea M. Cesura, David Thomson, Doris Riether, Andreas Ebneth, Lifen Wu, Renée Zindell and Monika Ermann and has published in prestigious journals such as Scientific Reports, Journal of Neurology Neurosurgery & Psychiatry and Drug Discovery Today.

In The Last Decade

Mark J. Gemkow

15 papers receiving 377 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark J. Gemkow Germany 11 231 117 116 115 50 15 389
Sylvain Célanire France 13 341 1.5× 169 1.4× 60 0.5× 216 1.9× 48 1.0× 24 572
Albert J. Uveges United States 9 401 1.7× 72 0.6× 187 1.6× 198 1.7× 76 1.5× 11 658
Kamil Kuder Poland 16 406 1.8× 246 2.1× 117 1.0× 122 1.1× 47 0.9× 47 640
Shalini Dogra India 15 346 1.5× 46 0.4× 60 0.5× 285 2.5× 64 1.3× 28 617
Sandra L. Cockerham United States 10 188 0.8× 44 0.4× 47 0.4× 210 1.8× 83 1.7× 25 521
Stéphanie Carvalho France 13 314 1.4× 45 0.4× 42 0.4× 295 2.6× 68 1.4× 16 632
Jill M. Wetter United States 15 316 1.4× 284 2.4× 42 0.4× 118 1.0× 139 2.8× 22 646
Shilina Roman United Kingdom 15 152 0.7× 71 0.6× 97 0.8× 38 0.3× 60 1.2× 22 450
Marc Capet France 12 206 0.9× 101 0.9× 38 0.3× 89 0.8× 44 0.9× 26 351
Seong-Geun Hong South Korea 15 314 1.4× 18 0.2× 52 0.4× 97 0.8× 81 1.6× 26 516

Countries citing papers authored by Mark J. Gemkow

Since Specialization
Citations

This map shows the geographic impact of Mark J. Gemkow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. Gemkow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. Gemkow more than expected).

Fields of papers citing papers by Mark J. Gemkow

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark J. Gemkow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. Gemkow. The network helps show where Mark J. Gemkow may publish in the future.

Co-authorship network of co-authors of Mark J. Gemkow

This figure shows the co-authorship network connecting the top 25 collaborators of Mark J. Gemkow. A scholar is included among the top collaborators of Mark J. Gemkow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark J. Gemkow. Mark J. Gemkow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Davenport, Adam J., Ioana Berindan‐Neagoe, Markus Koch, et al.. (2021). Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers. Scientific Reports. 11(1). 19877–19877. 40 indexed citations
2.
Hickey, Eugene R., Renée Zindell, Pier F. Cirillo, et al.. (2014). Selective CB2 receptor agonists. Part 1: The identification of novel ligands through computer-aided drug design (CADD) approaches. Bioorganic & Medicinal Chemistry Letters. 25(3). 575–580. 19 indexed citations
3.
Bartolozzi, Alessandra, Pier F. Cirillo, Eugene R. Hickey, et al.. (2014). Selective CB2 receptor agonists. Part 3: The optimization of a piperidine-based series that demonstrated efficacy in an in vivo neuropathic pain model. Bioorganic & Medicinal Chemistry Letters. 25(3). 587–592. 12 indexed citations
4.
Riether, Doris, Renée Zindell, Lifen Wu, et al.. (2014). Selective CB2 receptor agonists. Part 2: Structure–activity relationship studies and optimization of proline-based compounds. Bioorganic & Medicinal Chemistry Letters. 25(3). 581–586. 13 indexed citations
5.
Carty, Nikisha, Laura S. Schmidt, Caroline Graff, et al.. (2014). M20 Activation Of The Trkb Receptor Pathway Using A Novel Monoclonal Antibody Agonist: Implications For The Treatment Of Huntington's Disease. Journal of Neurology Neurosurgery & Psychiatry. 85(Suppl 1). A101–A101. 1 indexed citations
6.
Maillard, Michel, Celia Dominguez, Mark J. Gemkow, et al.. (2013). A Label-Free LC/MS/MS-Based Enzymatic Activity Assay for the Detection of Genuine Caspase Inhibitors and SAR Development. SLAS DISCOVERY. 18(8). 868–878. 3 indexed citations
7.
Maillard, Michel, Frederick A. Brookfield, Stephen M. Courtney, et al.. (2011). Exploiting differences in caspase-2 and -3 S2 subsites for selectivity: Structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors. Bioorganic & Medicinal Chemistry. 19(19). 5833–5851. 29 indexed citations
8.
Zindell, Renée, John Scott, Patricia Amouzegh, et al.. (2011). Aryl 1,4-diazepane compounds as potent and selective CB2 agonists: Optimization of drug-like properties and target independent parameters. Bioorganic & Medicinal Chemistry Letters. 21(14). 4276–4280. 9 indexed citations
9.
Riether, Doris, Lifen Wu, Pier F. Cirillo, et al.. (2011). 1,4-Diazepane compounds as potent and selective CB2 agonists: Optimization of metabolic stability. Bioorganic & Medicinal Chemistry Letters. 21(7). 2011–2016. 13 indexed citations
10.
Davenport, Adam J., Clemens Möller, Alexander Heifetz, et al.. (2010). Using Electrophysiology and In Silico Three-Dimensional Modeling to Reduce Human Ether-à-go-go Related Gene K + Channel Inhibition in a Histamine H3 Receptor Antagonist Program. Assay and Drug Development Technologies. 8(6). 781–789. 12 indexed citations
11.
East, Stephen P., Christian Eickmeier, Adam Flegg, et al.. (2010). An orally bioavailable positive allosteric modulator of the mGlu4 receptor with efficacy in an animal model of motor dysfunction. Bioorganic & Medicinal Chemistry Letters. 20(16). 4901–4905. 36 indexed citations
12.
Davenport, Adam J., Christopher C. Stimson, Massimo Corsi, et al.. (2010). Discovery of substituted benzyl tetrazoles as histamine H3 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 20(17). 5165–5169. 5 indexed citations
13.
Gemkow, Mark J., et al.. (2009). The histamine H3 receptor as a therapeutic drug target for CNS disorders. Drug Discovery Today. 14(9-10). 509–515. 154 indexed citations
14.
Zindell, Renée, Doris Riether, Todd Bosanac, et al.. (2009). Morpholine containing CB2 selective agonists. Bioorganic & Medicinal Chemistry Letters. 19(6). 1604–1609. 16 indexed citations
15.
Ermann, Monika, Doris Riether, Mark L. Brewer, et al.. (2008). Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity. Bioorganic & Medicinal Chemistry Letters. 18(5). 1725–1729. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sylvain Célanire Breakdown of academic impact, for papers by Albert J. Uveges Breakdown of academic impact, for papers by Kamil Kuder Breakdown of academic impact, for papers by Shalini Dogra Breakdown of academic impact, for papers by Sandra L. Cockerham Breakdown of academic impact, for papers by Stéphanie Carvalho Breakdown of academic impact, for papers by Jill M. Wetter Breakdown of academic impact, for papers by Shilina Roman Breakdown of academic impact, for papers by Marc Capet Breakdown of academic impact, for papers by Seong-Geun Hong
Rankless by CCL
2026